Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that CorMedix Inc. made materially false and/or misleading statements and/or failed to disclose that: On January 8, 2026, before the market opened, CorMedix published preliminary fourth quarter and full year 2025 results disclosing that its major revenue driver DefenCath would change its reimbursement policy change beginning on July 1, 2026. Management noted that the transition from its current TDAPA for DefenCath was expected to significantly reduce institutional reimbursement levels and net pricing in the second half of 2026. As a result, CorMedix lowered its full year revenue guidance from $400M down to $300M - $320M. Following this news, CRMD’s stock price fell over 21% to open at $8.73 per share.
In order to be eligible to join the CRMD class action lawsuit, you must have incurred a loss on shares of CorMedix Inc. purchased during the class period listed above.
TOP
